Suppression of high lipid diet induced by atherosclerosis sarpogrelate

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2394-2400

  Xu, Yan Jun ^a   Zhang, Ming ^b   Ji, Lei ^b   Elimban, Vijayan ^a   Chen, Li ^b   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b JILIN UNIVERSITY   (China)

Author keywords

Atherosclerosis; Blood viscosity; High cholesterol diet; Oxidative stress; Sarpogrelate

Indexed keywords

ANTITHROMBOCYTIC AGENT; MALONALDEHYDE; SARPOGRELATE; SEROTONIN 2 ANTAGONIST; SUCCINIC ACID DERIVATIVE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD; BLOOD VISCOSITY; CHOLESTEROL INTAKE; DRUG EFFECT; FOAM CELL; LIPID DIET; MALE; OXIDATIVE STRESS; RABBIT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; BLOOD VISCOSITY; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; FOAM CELLS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; RABBITS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SUCCINATES; SUPEROXIDE DISMUTASE; TRIGLYCERIDES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 84866763580     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01554.x     Document Type: Article

References (34)

1. Saini HK, Takeda N, Goyal RK, et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2004; 22: 27-54.
2. Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther. 1999; 290: 475-81.
3. Nagatomo T, Rashid M, Muntasir HA, et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004; 104: 59-81.
4. Sanganalmath SK, Barta J, Takeda N, et al. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myoscardial infarction. Can J Physiol Pharmacol. 2008; 86: 180-9.
5. Nishihira K, Yamashita A, Tanaka N, et al. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006; 4: 247-55.
6. Rajesh KG, Suzuki R, Maeda H, et al. 5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. Life Sci. 2006; 79: 1749-55.
7. Lizhka K, Hamaue N, Machida T, et al. Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009; 34: 18-30.
8. Shimizu Y, Minatoguchi S, Hashimoto K, et al. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol. 2002; 40: 1347-55.
9. Saini K, Sharma SK, Zahradka P, et al. Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate. Can J Physiol Pharmacol. 2003; 81: 1056-63.
10. Hayashi T, Sumi D, Matsui-Hirai H, et al. Sarpogrelate HCL, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis. 2003; 168: 23-31.
11. Ercan M, Konukoglu D, Erdem Yesim T. Association of plasma viscosity with cardiovascular risk factors in obesity: an old marker, a new insight. Clin Hemorheol Microcirc. 2006; 35: 441-6.
12. Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis. 2002; 161: 433-9.
13. Bosch T, Wendler T, Jaeger BR, et al. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther Apher. 2002; 5: 372-6.
14. Ren H, Li M, Feng L, et al. Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model. J Cardiovas Pharmacol. 2010; 55: 617-24.
15. Xu YJ, Chen Z, Liu J, et al. Effect of panaxadiol saponins on blood rheology. Yao Xue Tong Bao. 1988; 23: 284-6.
16. Adameova A, Xu YJ, Duhamel TA, et al. Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Curr Pharm Des. 2009; 15: 3094-107.
17. Duhamel TA, Xu YJ, Arneja AS, et al. Targeting platelets for the prevention and treatment of cardiovascular disease. Expert Opin Ther Targets. 2007; 11: 1523-33.
18. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006; 111: 674-706.
19. Xu YJ, Aziz OA, Bhugra P, et al. Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can J Cardiol. 2003; 19: 1525-36.
20. Xu YJ, Rathi SS, Chapman DC, et al. Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003; 41: 381-7.
21. Yamakawa J, Takahashi T, Saegusa S, et al. Effect of serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J Int Med Res. 2004; 32: 166-9.
22. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998; 140: 271-80.
23. Stoltz JF, Donner M. New trends in clinical hemorheology: an introduction to the concept of the hemorheological profile. Schweiz Med Wochenschr Suppl. 1991; 43: 41-9.
24. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010; 21: 312-8.
25. Haidari M, Ali M, Gangehei L, et al. Increased oxidative stress in atherosclerosis-predisposed regions of the mouse aorta. Life Sci. 2010; 87: 100-10.
26. Oyama J, Satoh S, Suematsu N, et al. Scavenging free radicals improves endothelial dysfunction in human coronary arteries in vivo. Heart Vessels. 2010; 25: 379-85.
27. Michel F, Bonnefont-Rousselot D, Mas E, et al. Biomarkers of lipid peroxidation: analytical aspects. Ann Biol Clin (Paris). 2008; 66: 605-20.
28. Johnston TP, Zhou X. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice resulats from an indirect effect. J Cardiovasc Pharmacol. 2007; 49: 246-52.
29. Yang RL, Shi YH, Hao G, et al. Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr. 2008; 43: 254-8.
30. Sun YM, Su Y, Jin HB, et al. Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int J Cardiol. 2011; 147: 383-7.
31. Iwabayashi M, Taniyama Y, Sanada F, et al. Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT/Akt/eNOS pathway in diabetic mice. Atherosclerosis. 2012; 220: 337-42.
32. Isogawa A, Yamakado M, Yano M, et al. Serum superoxide dismutase activity correlates with the components of metabolic syndrome or carotid artery intima-media thickness. Diabetes Res Clin Pract. 2009; 86: 213-8.
33. Origuchi N, Shigematsu H, Muto T. Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hyper cholesterolaemic rabbit. Int Angiol. 1997; 16: 204-9.
34. Kodama A, Komori K, Hattori K, et al. Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. J Vasc Surg. 2009; 49: 1272-81.